Holen Sie sich die Stockscreener-App
2.37
2.16%
0.05
Handel nachbörslich:
2.35
-0.02
-0.84%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin - AD HOC NEWS
Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com
Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion - Yahoo Finance
How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX) - simplywall.st
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 2000 Index - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark - marketscreener.com
Here's why you should add LXRX stock to your portfolio now - MSN
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 3000E Index - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark - marketscreener.com
LXRX Surges As Traders Pounce On Strong Breakout - StocksToTrade
LXRX Jumps As Traders Focus On Breakout Momentum - timothysykes.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders - StocksToTrade
LXRX Climbs As Bulls Press Multi-Day Breakout - timothysykes.com
Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals stock hits 52-week high at $2.53 - Investing.com UK
Lexicon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LXRX) - TradingView
LXRX Forecast — Price Target — Prediction for 2027 - TradingView
Lexicon Pharmaceuticals debuts HCM education booth at heart failure conference - Traders Union
Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Here's Why You Should Add LXRX Stock to Your Portfolio Now - Yahoo Finance
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Lexicon Pharmaceuticals StockSunday background on strategy and trials - AD HOC NEWS
LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill
Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Institutional Confidence - TradingKey
Lexicon Pharmaceuticals Inc - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Peripheral Neuropathic Pain Market Positioned for Significant Commercial Growth by 2034 – DelveInsight | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith - Barchart.com
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - Insider Monkey
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings - Stock Titan
Diane E. Sullivan converts 89,312 RSUs at Lexicon Pharmaceuticals (LXRX) - Stock Titan
[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Lexicon Pharmaceuticals (LXRX) director exercises 89,312 RSUs into shares - Stock Titan
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 restricted stock units into common stock - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 RSUs into common stock, boosts stake - Stock Titan
LXRX: Pivotal HCM trial nears completion as pipeline and partnerships drive transformation - TradingView
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates - Yahoo Finance
Lexicon Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cheung Ivan - Moomoo
New Type 1 diabetes drug data from Lexicon at ADA 2026 meeting - Stock Titan
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions - The Manila Times
Lexicon (LXRX) Q1 2026 Earnings Transcript - The Globe and Mail
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):